NASDAQ:CTSO Cytosorbents Q3 2024 Earnings Report $4.30 -0.61 (-12.42%) Closing price 03:58 PM EasternExtended Trading$4.41 +0.11 (+2.60%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cytosorbents EPS ResultsActual EPS-$1.60Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACytosorbents Revenue ResultsActual Revenue$8.61 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACytosorbents Announcement DetailsQuarterQ3 2024Date1/3/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCytosorbents' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Cytosorbents Earnings HeadlinesCytoSorbents Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 23 at 7:00 AM | prnewswire.comCytoSorbents op H.C. Wainwright conferentie: breakeven, medicijnhoopSeptember 16, 2026 | nl.investing.comAI Panic: Sell now or wait?Bank of America, Goldman Sachs, and Morgan Stanley have reportedly warned private clients about a coming stock market crisis. Business Insider says it could mean a brutal decade ahead for stocks, one that could keep portfolios in the red well into the 2030s. New technology may offer a way to prepare before the warning plays out.September 24 at 1:00 AM | TradeSmith (Ad)CytoSorbents出席H.C. Wainwright大会：接近盈亏平衡，新药前景可期September 16, 2026 | cn.investing.comCytosorbents consensus price target increased by 1,900% to $48.45September 15, 2026 | msn.comCytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | prnewswire.comSee More Cytosorbents Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email. Email Address About CytosorbentsCytosorbents (NASDAQ:CTSO) develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components. The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis. CytoSorbents also markets or develops related products, including DrugSorb-ATR, which is designed to remove certain antiplatelet and anticoagulant drugs during cardiac surgery, and VetResQ, a veterinary blood-purification product. CytoSorbents is headquartered in Princeton, New Jersey, and serves international markets through regulatory clearances, distributors and commercial partnerships. CytoSorb has been available in Europe and other markets outside the United States, while certain additional products and indications remain subject to regulatory review or clinical development. The company’s products are intended for use with established extracorporeal treatment systems in hospitals and other clinical settings.View Cytosorbents ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
